Health-Care Innovation in Emerging Markets

  • Françoise Simon
Part of the International Political Economy Series book series (IPES)


Major emerging markets such as India, China, and Brazil, in addition to presenting rising middle-class populations, are now playing a part in driving the transformation of the health-care sector, from R&D and clinical trials to local manufacturing.


World Trade Organization Foreign Firm Purchase Power Parity Universal Health Coverage Intellectual Property Protection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abuduxike, A. and Aljunid, S. (2012). “Development of Health Biotechnology in Developing Countries: Can Private-Sector Players Be the Prime Movers?” Biotechnology Advances, 30: 1589–601.CrossRefGoogle Scholar
  2. Biocon (2015). Biocon company data, Company History. Retrieved from Scholar
  3. Booz & Company. (2011). “Pharma Emerging Markets 2.0: How Emerging Markets Are Driving the Transformation of the Pharmaceutical Industry.” Booz & Company. Retrieved from Scholar
  4. Burns, L. (ed.). (2014). India’s Healthcare Industry. Cambridge: Cambridge University Press.Google Scholar
  5. Daemmrich, A. and McKown Cornell, I. (2012). “GlaxoSmithKline in Brazil: Public/Private Vaccine Partnership,” Harvard Business School, Case 9–712–049, June.Google Scholar
  6. Fabre, G. (2014). “The Real Leap Forward: China’s Ramp;D and Innovation Strategy.” In Taylor, R. (ed.) The Globalization of Chinese Business. Implications for Multinational Investors (pp. 3–25 ). Oxford, UK: Elsevier/Chandos Publishing.CrossRefGoogle Scholar
  7. Frew, S. (2014). “India’s Biotechnology Sector.” In Burns, L. (ed.) India’s Healthcare Industry (pp. 477–99 ). Cambridge: Cambridge University Press.CrossRefGoogle Scholar
  8. Gragnolati, M., Lindelow, M., and Couttolenc, B. (2012). Twenty Years of Health System Reform in Brazil–An Assessment of the Sistema Unico de Saude. Washington, DC: World Bank.Google Scholar
  9. Herzlinger, R. and Kindred, N. (2014). “Shanghai Pharmaceuticals.” Harvard Business School, Case 9–313–016, 2014.Google Scholar
  10. IBEF (India Brand Equity Foundation). (2014). “Biotechnology Industry in India.” Retrieved from
  11. IMS Institute for Healthcare Informatics. (2013). “The Global Use of Medicines: Outlook through 2017.” Retrieved from Scholar
  12. IMS Institute for Healthcare Informatics. (2014). “Harbingers of Change in Healthcare.” Retrieved from Scholar
  13. La Forgia, G. and Nagpal, S. (2012). Government-Sponsored Health Insurance in India–Are You Covered? Washington, DC: World Bank.CrossRefGoogle Scholar
  14. Lawton R. B. (ed.) (2014), India’s Healthcare Industry. Cambridge: Cambridge University Press.Google Scholar
  15. Li, Y., Lu, J., Tao, Z., and Wei, S -J. (2010). Viagra in China: A Prolonged Battle over Intellectual Property Rights. Asia Case Research Centre, University of Hong Kong, Case HKU902.Google Scholar
  16. Lima, M. (2015). “Brazil Analysts Raise Inflation, Cut GDP Forecast for Third Week.” Bloomberg News. Retrieved from–01–19/brazil–analysts–raise–inflation–cut–gdp–forecast–for–third–week.htmlGoogle Scholar
  17. MOITI (Massachusetts Office of International Trade and Investment). (2008). “Brazil Biotechnology Industry.” Retrieved from Google Scholar
  18. Morel, C. M., Tara, A., Denis, B., et al. (2005). “Health Innovation Networks to Help Developing Countries Address Neglected Diseases.” Science, 309 (5733): 401–4.CrossRefGoogle Scholar
  19. Mori Sarti, F., Ivanauskas, T., Montoya Diaz, M., and Coelho Campino, A. C. (2012). Towards Universal Health Coverage in Latin America and the Caribbean: Case Study Measuring Inequalities in Health in Brazil. Washington, DC: World Bank.Google Scholar
  20. Resende, V. (2012). The Biotechnology Market in Brazil. Washington, DC: US Department of Commerce.Google Scholar
  21. Sachan, N., Tathambothia, A., Nehru, R., and Dharanaj, C. (2013). Collaborative Commercialization at Gilead Sciences: Resolving the Innovation vs. Access Tradeoff. Indian School of Business, Case ISB 025, 2013.Google Scholar
  22. Specter, M. (2014). “The Gene Factory.” The New Yorker. Retrieved from Google Scholar
  23. Tao, Z. (2014). The GSK Scandal: When Questionable Global Practices Met Imperfect Institutions in Emerging Markets. Asia Case Research Centre, University of Hong Kong, Case HK 1049.Google Scholar
  24. Tyagi, S., Mahajan, V., and Nauriyal, D. K. (2014). “Innovations in the Indian Drug and Pharmaceutical Industry: Have They Impacted Exports?” Journal of Intellectual Property Rights, 19: 243–52. Retrieved from Scholar
  25. Wang, K., Hong, J., Marinova, D., and Zhu, L. (2009). “Evolution and Governance of the Biotechnology and Pharmaceutical Industry in China.” Mathematics and Computers in Simulation, 79 (9): 2947–56.CrossRefGoogle Scholar
  26. World Bank. (2013). Brazil Report, 2013. Washington, DC: World Bank.Google Scholar
  27. World Health Organization. (2013). World Health Report 2013. Geneva: Research for Universal Health Coverage.Google Scholar
  28. Yu, X., Li, C., Shi, Y., and Yu, M. (2010). “Pharmaceutical Supply Chain in China: Current Issues and Implications for Health System Reform.” Health Policy, 97 (1): 8–15.CrossRefGoogle Scholar

Copyright information

© Françoise Simon 2016

Authors and Affiliations

  • Françoise Simon

There are no affiliations available

Personalised recommendations